

# Accepted Manuscript

Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated with Second-Line Therapies for Medicare Patients with Advanced Non-Small Cell Lung Cancer

Ashwini Arunachalam, MPH, BDS, Haojie Li, MD, PhD, Marisa A. Bittoni, PhD, Ramon Camacho, PhD, Xiting Cao, PhD, Yichen Zhong, MHS, Gregory M. Lubiniecki, MD, David P. Carbone, MD, PhD

PII: S1525-7304(18)30136-0

DOI: [10.1016/j.clcc.2018.05.016](https://doi.org/10.1016/j.clcc.2018.05.016)


Reference: CLLC 809

To appear in: *Clinical Lung Cancer*

Received Date: 22 December 2017

Revised Date: 19 May 2018

Accepted Date: 28 May 2018



Please cite this article as: Arunachalam A, Li H, Bittoni MA, Camacho R, Cao X, Zhong Y, Lubiniecki GM, Carbone DP, Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated with Second-Line Therapies for Medicare Patients with Advanced Non-Small Cell Lung Cancer, *Clinical Lung Cancer* (2018), doi: 10.1016/j.clcc.2018.05.016.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title page

**Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated with Second-Line Therapies for Medicare Patients with Advanced Non-Small Cell Lung Cancer**

***Running head: Second-line therapy for advanced NSCLC***

Ashwini Arunachalam, MPH, BDS,<sup>a,\*</sup> Haojie Li, MD, PhD,<sup>b</sup> Marisa A. Bittoni, PhD,<sup>c</sup> Ramon Camacho, PhD,<sup>b</sup> Xiting Cao, PhD,<sup>a</sup> Yichen Zhong, MHS,<sup>d</sup> Gregory M. Lubiniecki, MD,<sup>b</sup> David P. Carbone, MD, PhD<sup>c</sup>

<sup>a</sup>Center for Observational and Real World Evidence (CORE), Merck & Co., Inc., Rahway, NJ, USA

<sup>b</sup>Merck & Co., Inc., Kenilworth, NJ, USA

<sup>c</sup>The Ohio State University Comprehensive Cancer Center and James Thoracic Oncology Center, The Ohio State University, Columbus, OH, USA

<sup>d</sup>Biostatistics and Research Decision Sciences (BARDS), Merck & Co., Inc., North Wales, PA, USA

\*Corresponding author: Ashwini Arunachalam, MPH, BDS, Center for Observational and Real World Evidence (CORE), Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, NJ, 07065.

Phone: +1-732-594-2947, fax: +1-732-594-4910, E-mail: ashwini.arunachalam@merck.com

**Funding:** This work was supported by Merck & Co., Inc., Kenilworth, NJ, USA.

Download English Version:

<https://daneshyari.com/en/article/8950893>

Download Persian Version:

<https://daneshyari.com/article/8950893>

[Daneshyari.com](https://daneshyari.com)